You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBeclomethasone dipropionate
Accession NumberDB00394  (APRD00564)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBeclomethasone dipropionate is a prodrug of the free form, Beclomethasone (beclomethasone-17-monopropionate). An anti-inflammatory, synthetic corticosteroid, it is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma and allergic rhinitis (seasonal and perennial). Beclometasone dipropionate is also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease. It is marketed under several brand names such as Qnasl (US) and Rivanase AQ (Canada).
Structure
Thumb
Synonyms
(11beta,16beta)-9-chloro-11-Hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
9-chloro-11beta-Hydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
9-chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione
9-chloro-16beta-Methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate
9α-chloro-16β-methylprednisolone
Beclometasone
Beclometasone 17,21-dipropionate
Beclometasone dipropionate
Beclomethasone dipropionate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-beclomethasone Dipropionate Inhaler 50mcg/mdAerosol, metered50 mcgRespiratory (inhalation)Altimed Pharma Inc.1992-12-312005-05-27Canada
Beclodisk - Pwr Inh 100mcg/blisterPowder100 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1997-09-032000-05-24Canada
Beclodisk - Pwr Inh 200mcg/blisterPowder200 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1997-06-112000-05-24Canada
Beclodisk Pwr 100mcg/blisterPowder100 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Beclodisk Pwr 200mcg/blisterPowder200 mcgRespiratory (inhalation)Glaxo Canada Inc1989-12-311998-07-30Canada
Becloforte 250mcg/aemAerosol, metered250 mcgRespiratory (inhalation)Glaxo Canada Inc1988-12-311998-07-30Canada
Becloforte Inhaler - Aem Inh 250mcg/aemAerosol, metered250 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1997-02-112000-05-24Canada
Beclomethasone Aqueous Nasal Spray 50mcg/metered DoseAerosol, metered; Suspension50 mcgNasalPrempharm Inc1997-01-052005-08-05Canada
Beclomethasone Dipropionate Nas-spr 50mcg/aemAerosol, metered50 mcgNasalKenral Inc.1992-12-311997-08-11Canada
Beclomethasone Dipropionate Nasal InhalerAerosol, metered50 mcgNasal; Respiratory (inhalation)Pharmaco Canada Inc.1994-12-312001-07-18Canada
Beclomethasone Dipropionate Oral InhalerAerosol, metered50 mcgOral; Respiratory (inhalation)Pharmaco Canada Inc.1994-12-312001-07-18Canada
Beclovent - Aem 50mcg/aemAerosol, metered50 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1998-03-302000-05-24Canada
Beclovent Aem 50mcg/aemAerosol, metered50 mcgRespiratory (inhalation)Glaxo Canada Inc1975-12-311998-07-30Canada
Beclovent Rotacaps - Inh 100mcg/capsuleCapsule100 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1998-11-302000-05-24Canada
Beclovent Rotacaps - Inh 200mcg/capCapsule200 mcgRespiratory (inhalation)Glaxo Wellcome Inc.1998-03-302000-05-24Canada
Beclovent Rotacaps 100mcgCapsule100 mcgRespiratory (inhalation)Glaxo Canada Inc1985-12-312000-08-02Canada
Beclovent Rotacaps 200mcgCapsule200 mcgRespiratory (inhalation)Glaxo Canada Inc1985-12-311998-07-30Canada
Beconase AQSpray, suspension42 ug/1NasalGlaxo Smith Kline Llc1989-10-01Not applicableUs
Beconase AQSpray, suspension42 ug/1NasalSTAT Rx USA LLC1989-10-01Not applicableUs
Beconase AQSpray, suspension42 ug/1NasalA S Medication Solutions Llc1989-10-01Not applicableUs
Beconase AQ Nasal Aem 50mcg/aemAerosol, metered50 mcgNasalGlaxo Canada Inc1991-12-312000-05-24Canada
Beconase Nasal Aem 50mcg/aemAerosol, metered50 mcgNasalGlaxo Canada Inc1991-12-311996-09-10Canada
Mylan-beclo AQAerosol, metered; Suspension50 mcgNasalMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Nu-beclomethasone 50 Mcg/metered Nasal SpraySuspension50 mcgNasalNu Pharm Inc1998-11-242012-09-04Canada
PropadermCream0.025 %TopicalValeant Canada Lp/valeant Canada s.e.c.1998-03-30Not applicableCanada
Propaderm Cream 0.025%Cream.025 %TopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1989-12-151998-07-29Canada
Propaderm Lot 0.025%Lotion.025 %TopicalAllen & Hanburys A Glaxo Canada Ltd. Co.1973-12-311996-09-10Canada
Propaderm Lotion 0.025%Lotion0.025 %TopicalShire Biochem Inc1996-07-302005-12-09Canada
QnaslAerosol, metered40 ug/1NasalTeva Respiratory, LLC2015-02-01Not applicableUs
QnaslAerosol, metered80 ug/1NasalTeva Respiratory, LLC2012-04-13Not applicableUs
QvarAerosol, metered80 ug/1Respiratory (inhalation)Teva Respiratory, LLC2011-01-21Not applicableUs
QvarAerosol, metered40 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2008-01-29Not applicableUs
QvarAerosol, metered80 ug/1Respiratory (inhalation)A S Medication Solutions2014-09-15Not applicableUs
QvarAerosol, metered80 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2008-01-29Not applicableUs
QvarAerosol, metered40 ug/1Respiratory (inhalation)STAT Rx USA LLC2000-09-15Not applicableUs
QvarAerosol, metered50 mcgRespiratory (inhalation)Valeant Canada Lp Valeant Canada S.E.C.2000-05-29Not applicableCanada
QvarAerosol, metered40 ug/1Respiratory (inhalation)Teva Respiratory, LLC2011-01-19Not applicableUs
QvarAerosol, metered40 ug/1Respiratory (inhalation)Teva Respiratory, LLC2000-10-062015-11-30Us
QvarAerosol, metered100 mcgRespiratory (inhalation)Valeant Canada Lp Valeant Canada S.E.C.2000-05-29Not applicableCanada
Ratio-beclomethasone AQSpray50 mcgNasalRatiopharm Inc Division Of Teva Canada Limited1995-12-312010-05-21Canada
Rivanase AQ.nasal Spray 50mcg/metered DoseAerosol, metered50 mcgNasalLaboratoire Riva Inc1997-08-27Not applicableCanada
Vancenase Aer 50mcgAerosol, metered50 mcgNasal; Respiratory (inhalation)Schering Plough Canada Inc1978-12-312001-07-18Canada
Vanceril Aem 50mcgAerosol, metered50 mcgOral; Respiratory (inhalation)Schering Plough Canada Inc1976-12-312004-07-21Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-beclomethasone Nasal SpraySuspension50 mcgNasalApotex Inc1998-10-07Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AerobecTeva
AldecinSchering-Plough
AnceronNot Available
AndionNot Available
BeclacinMayado Seiyaku
BecloforteGlaxoSmithKline
BeclometOrion
BeclorhinolChiesi
BeclovalNot Available
BecloventGlaxoSmithKline
BecodisksGlaxoSmithKline
BeconaseGlaxoSmithKline
BeconasolNot Available
BecotideGlaxoSmithKline
Clenil-ANot Available
EntydermaNot Available
InaloneGlaxoSmithKline
KorbutoneNot Available
orBecDOR BioPharma, Inc.
Rino-ClenilChiesi
RivanaseNot Available
SanasthmaxChiesi
SanasthmylNot Available
VancenaseNot Available
VancerilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Beclomethasone dipropionate monohydrate
77011-63-3
Thumb
  • InChI Key: QHQJZIXSVLFOHD-LYRZEVDOSA-N
  • Monoisotopic Mass: 538.2333459
  • Average Mass: 539.06
DBSALT001373
Categories
UNII5B307S63B2
CAS number5534-09-8
WeightAverage: 521.042
Monoisotopic: 520.222781245
Chemical FormulaC28H37ClO7
InChI KeyKUVIULQEHSCUHY-XYWKZLDCSA-N
InChI
InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
IUPAC Name
2-[(1R,2S,10S,11S,13S,14R,15S,17S)-1-chloro-17-hydroxy-2,13,15-trimethyl-5-oxo-14-(propanoyloxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
SMILES
[H][C@@]12C[[email protected]](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[[email protected]](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationUsed in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
Structured Indications
PharmacodynamicsBeclometasone, a synthetic halogenated glucocorticoid with antiinflammatory and vasoconstrictive effects, is used for treating steroid-dependent asthma, allergic or nonallergic rhinitis, or recurrent nasal polyps.
Mechanism of actionUnbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. For the investigated use in the treatment of GvHD or Crohn's, beclometasone acts by binding to interleukin-13 to inhibit cytokines, which in turn inhibits inflammatory chemicals downstream.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionMean peak plasma concentration was 88pg/ml at 0.5 hour
Volume of distribution

The steady state volume of distribution for beclomethasone dipropionate is 20 L, and for it’s active metabolite, beclomethasone-17-monopropionate, it is much larger at 424 L.

Protein binding87% to albumin and transcortin
Metabolism

Metabolism mediated via esterase enzymes that are found in most tissues. Undergoes rapid and extensive conversion to beclomenthasone-17-monopropionate (17-BMP) during absorption

Route of eliminationIrrespective of the route of administration (injection, oral or inhalation), BDP and its metabolites are mainly excreted in the feces. Less than 10% of the drug and its metabolites are excreted in the urine.
Half life2.8 hours
Clearance

High plasma clearance after intravenous administration (150 and 120 L/hour).

ToxicityThe acute toxicity of beclometasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclometasone dipropionate over a long period could lead to adrenal suppression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Beclomethasone dipropionate.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Beclomethasone dipropionate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Beclomethasone dipropionate.Approved
AldesleukinBeclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Beclomethasone dipropionate.Approved
AmiodaroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BBeclomethasone dipropionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Beclomethasone dipropionate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Beclomethasone dipropionate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Beclomethasone dipropionate.Approved, Investigational
AprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Beclomethasone dipropionate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Beclomethasone dipropionate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Beclomethasone dipropionate.Approved, Investigational
BazedoxifeneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Beclomethasone dipropionate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Beclomethasone dipropionate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Beclomethasone dipropionate.Investigational
Bismuth SubcitrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Beclomethasone dipropionate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Beclomethasone dipropionate.Investigational
BumetanideBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Beclomethasone dipropionate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Beclomethasone dipropionate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Beclomethasone dipropionate.Experimental
CDX-110The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
CeritinibBeclomethasone dipropionate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Beclomethasone dipropionate.Approved, Vet Approved
ChlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneBeclomethasone dipropionate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Beclomethasone dipropionate.Approved
CobicistatThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Beclomethasone dipropionate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Beclomethasone dipropionate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Beclomethasone dipropionate.Investigational
DarunavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Beclomethasone dipropionate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Beclomethasone dipropionate.Approved, Vet Approved
DienestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.Approved
DihydrotestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Beclomethasone dipropionate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Beclomethasone dipropionate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Beclomethasone dipropionate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Beclomethasone dipropionate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Beclomethasone dipropionate.Approved
EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.Approved
Etacrynic acidBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Beclomethasone dipropionate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Beclomethasone dipropionate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Beclomethasone dipropionate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Beclomethasone dipropionate.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Beclomethasone dipropionate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Beclomethasone dipropionate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Beclomethasone dipropionate.Approved
FenthionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Beclomethasone dipropionate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Beclomethasone dipropionate.Vet Approved
FluoxymesteroneBeclomethasone dipropionate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Beclomethasone dipropionate.Approved, Investigational
FosaprepitantThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Fosphenytoin.Approved
FurosemideBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Beclomethasone dipropionate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Beclomethasone dipropionate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Beclomethasone dipropionate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
HydrochlorothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Beclomethasone dipropionate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Beclomethasone dipropionate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Beclomethasone dipropionate.Approved
IdelalisibThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.Approved
IndapamideBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone dipropionate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Beclomethasone dipropionate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Beclomethasone dipropionate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Beclomethasone dipropionate.Withdrawn
ItraconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Beclomethasone dipropionate.Experimental
KetoconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Beclomethasone dipropionate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Beclomethasone dipropionate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Beclomethasone dipropionate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Beclomethasone dipropionate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Beclomethasone dipropionate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Beclomethasone dipropionate.Approved
LumacaftorThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Beclomethasone dipropionate.Approved, Investigational
MagaldrateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Beclomethasone dipropionate.Approved
Magnesium TrisilicateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Beclomethasone dipropionate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Beclomethasone dipropionate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Beclomethasone dipropionate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Beclomethasone dipropionate.Approved
MestranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Beclomethasone dipropionate.Withdrawn
MethallenestrilThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideBeclomethasone dipropionate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Minaprine.Approved
MitotaneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Beclomethasone dipropionate.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Beclomethasone dipropionate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Beclomethasone dipropionate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone dipropionate.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Beclomethasone dipropionate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Beclomethasone dipropionate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Beclomethasone dipropionate.Investigational
NefazodoneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Beclomethasone dipropionate.Approved
NevirapineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone dipropionate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Beclomethasone dipropionate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Beclomethasone dipropionate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Beclomethasone dipropionate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Beclomethasone dipropionate.Vet Approved
OxandroloneBeclomethasone dipropionate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone dipropionate.Approved
OxymetholoneBeclomethasone dipropionate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Beclomethasone dipropionate.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Beclomethasone dipropionate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Beclomethasone dipropionate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Beclomethasone dipropionate.Approved, Vet Approved
PhenytoinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Beclomethasone dipropionate.Approved, Investigational
PiretanideBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Beclomethasone dipropionate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Beclomethasone dipropionate.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideBeclomethasone dipropionate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Beclomethasone dipropionate.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Beclomethasone dipropionate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Quinestrol.Approved
QuinethazoneBeclomethasone dipropionate may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Beclomethasone dipropionate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate.Experimental, Investigational
RifabutinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Beclomethasone dipropionate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin.Approved
S EquolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone dipropionate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Beclomethasone dipropionate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Beclomethasone dipropionate.Approved
SaquinavirThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Beclomethasone dipropionate.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Beclomethasone dipropionate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Beclomethasone dipropionate.Investigational
St. John's WortThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololBeclomethasone dipropionate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Beclomethasone dipropionate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Beclomethasone dipropionate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Beclomethasone dipropionate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Beclomethasone dipropionate.Approved
TelithromycinThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Beclomethasone dipropionate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Beclomethasone dipropionate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Beclomethasone dipropionate.Approved
TestosteroneBeclomethasone dipropionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Beclomethasone dipropionate.Approved
TiboloneThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Beclomethasone dipropionate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Beclomethasone dipropionate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Beclomethasone dipropionate.Approved
TorasemideBeclomethasone dipropionate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Beclomethasone dipropionate.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trichlorfon.Vet Approved
TrichlormethiazideBeclomethasone dipropionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Beclomethasone dipropionate.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Beclomethasone dipropionate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinBeclomethasone dipropionate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Beclomethasone dipropionate.Approved
ZeranolThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Beclomethasone dipropionate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Beclomethasone dipropionate.Withdrawn
Food Interactions
  • No food effects were found when given with beclomethasone dipropionate.
References
Synthesis Reference

Taub, D., Wendler, N.L. and Slates, H.L.; US.Patent 3,345,387; October 3, 1967; assigned
to Merck & Co., Inc.

General References
  1. Willey RF, Milne LJ, Crompton GK, Grant IW: Beclomethasone dipropionate aerosol and oropharyngeal candidiasis. Br J Dis Chest. 1976 Jan;70(1):32-8. [PubMed:1259918 ]
  2. Salzman GA, Pyszczynski DR: Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol. 1988 Feb;81(2):424-8. [PubMed:3339197 ]
  3. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S: Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003 Jun;90(6):646-51. [PubMed:12839324 ]
  4. Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M: Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Biomed Pharmacother. 2007 Jul;61(6):370-6. Epub 2007 Mar 12. [PubMed:17399941 ]
  5. McDonald GB: Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation. Expert Opin Investig Drugs. 2007 Oct;16(10):1709-24. [PubMed:17922633 ]
  6. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB: A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007 May 15;109(10):4557-63. Epub 2007 Jan 23. [PubMed:17244684 ]
  7. Castilla C, Perez-Simon JA, Sanchez-Guijo FM, Diez-Campelo M, Ocio E, Perez-Persona E, Lopez-Villar O, Vazquez L, Caballero D, San Miguel JF: Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD). Biol Blood Marrow Transplant. 2006 Sep;12(9):936-41. [PubMed:16920559 ]
External Links
ATC CodesR03BA01R03AK08A07EA07D07CC04R01AD01D07AC15
AHFS Codes
  • 52:08.08
  • 68:04.00
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (255 KB)
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9851
Caco-2 permeable+0.5698
P-glycoprotein substrateSubstrate0.7529
P-glycoprotein inhibitor IInhibitor0.5986
P-glycoprotein inhibitor IINon-inhibitor0.7488
Renal organic cation transporterNon-inhibitor0.7907
CYP450 2C9 substrateNon-substrate0.8634
CYP450 2D6 substrateNon-substrate0.9174
CYP450 3A4 substrateSubstrate0.784
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8577
Ames testNon AMES toxic0.938
CarcinogenicityNon-carcinogens0.914
BiodegradationNot ready biodegradable0.9932
Rat acute toxicity2.1115 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9456
hERG inhibition (predictor II)Non-inhibitor0.6054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Schering corp sub schering plough corp
  • Schering corp
Packagers
Dosage forms
FormRouteStrength
SuspensionNasal50 mcg
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)200 mcg
Aerosol, meteredRespiratory (inhalation)250 mcg
Aerosol, meteredNasal; Respiratory (inhalation)50 mcg
Aerosol, meteredOral; Respiratory (inhalation)50 mcg
CapsuleRespiratory (inhalation)100 mcg
CapsuleRespiratory (inhalation)200 mcg
Spray, suspensionNasal42 ug/1
Aerosol, metered; suspensionNasal50 mcg
CreamTopical0.025 %
CreamTopical.025 %
LotionTopical.025 %
LotionTopical0.025 %
Aerosol, meteredNasal40 ug/1
Aerosol, meteredNasal80 ug/1
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredRespiratory (inhalation)40 ug/1
Aerosol, meteredRespiratory (inhalation)50 mcg
Aerosol, meteredRespiratory (inhalation)80 ug/1
SprayNasal50 mcg
Aerosol, meteredNasal50 mcg
Prices
Unit descriptionCostUnit
Beconase AQ 42 mcg/spray Suspension 25 gm Inhaler149.32USD inhaler
Beclomethasone dipro powder107.1USD g
Qvar 80 mcg/act Aerosol 7.3 gm Inhaler105.64USD inhaler
Qvar 40 mcg/act Aerosol 7.3 gm Inhaler87.5USD inhaler
Qvar 80 mcg inhaler19.05USD g
Qvar 40 mcg inhaler15.12USD g
Propaderm 250 mcg/g Cream0.46USD g
Qvar Cfc-Free 100 mcg/dose Metered Dose Aerosol0.33USD dose
Qvar Cfc-Free 50 mcg/dose Metered Dose Aerosol0.16USD dose
Apo-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
Mylan-Beclo Aq. 50 mcg/dose Metered Dose Spray0.06USD dose
Nu-Beclomethasone 50 mcg/dose Metered Dose Spray0.06USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776432 No1995-07-072015-07-07Us
US6446627 No1997-12-182017-12-18Us
US7780038 No2007-01-242027-01-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point117-120 °CNot Available
water solubility49.39 mg/LNot Available
logP1.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00208 mg/mLALOGPS
logP3.69ALOGPS
logP4.43ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)13.85ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.97 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity134.79 m3·mol-1ChemAxon
Polarizability54.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Dicarboxylic acid or derivatives
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Chlorohydrin
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Saklatvala J: Glucocorticoids: do we know how they work? Arthritis Res. 2002;4(3):146-50. Epub 2002 Jan 21. [PubMed:12010562 ]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850 ]
  3. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005 Sep 15;172(6):704-12. Epub 2005 Apr 28. [PubMed:15860753 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Landyshev IuS, Grigorenko AA, Marikhina NS, Molochnaia SV: [A comparative assessment of the effect of different methods of glucocorticosteroid therapy on the hypophyseal-adrenal system in bronchial asthma patients]. Ter Arkh. 1995;67(3):43-7. [PubMed:7770804 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:43